There is no good evidence that betahistine helps tinnitus: a 2018 Cochrane review of five placebo-controlled trials found an absence of evidence that it has any effect, and NICE's evidence review found no clinical difference from placebo. It is also one of the most widely prescribed drugs for tinnitus and dizziness-related conditions in parts of Europe, which is why the gap between the prescribing and the evidence is worth covering directly — it's likely to come up if you search for medication options.
What it is and why it's prescribed
Betahistine is a drug originally developed for Ménière's disease — a condition involving vertigo, fluctuating hearing loss, tinnitus, and ear fullness. It works on histamine receptors and is thought to increase blood circulation in the inner ear, the rationale behind its use for tinnitus specifically. It's important to know upfront: it is not licensed for tinnitus treatment in the UK, and per NICE's own review, there is currently no clinically proven drug treatment for tinnitus at all — betahistine's use for tinnitus specifically has always been somewhat off-label reasoning extended from its Ménière's disease indication.
What NICE's evidence review found
The UK's National Institute for Health and Care Excellence (NICE) conducted a formal review, as part of its 2020 tinnitus guideline, specifically asking whether betahistine is clinically and cost-effective for tinnitus. The conclusion is direct: the evidence showed no clinical difference between betahistine and placebo, with some possible harm shown specifically in people with tinnitus who did not have Ménière's disease. NICE's guidance goes further, stating that based on existing clinical evidence, betahistine would not be considered cost-effective, since it doesn't show improved health outcomes relative to its cost.
Even for Ménière's disease itself, the picture is mixed
This is a useful, honest complication: even for Ménière's disease — the condition betahistine was actually developed and approved for — the evidence is more contested than its widespread use suggests. A systematic review pooling 10 randomized controlled trials across 402 participants found no differences in hearing loss, tinnitus, or quality of life between betahistine and placebo, rating the certainty of this evidence as low to very low. A large, well-designed trial (the BEMED trial, described as adequately powered with low risk of bias) specifically found no evidence of a difference between betahistine and placebo for reducing vertigo, Ménière's disease's primary symptom. At the same time, a professional consensus conference of vestibular disorder specialists rated betahistine as useful for dizziness and vertigo specifically (87% agreement) while explicitly rating its efficacy for hearing loss, tinnitus, and ear fullness as low — a nuanced, split verdict from clinicians who use it regularly, not a blanket endorsement or rejection.
What Cochrane found
The highest-grade synthesis available on this question is a Cochrane review published in 2018, and it is worth quoting closely because Cochrane reviews are unusually careful about saying what they do not know.
It included five studies with 303 to 305 participants, all comparing betahistine against placebo in adults with subjective idiopathic tinnitus — four parallel-group randomised trials and one crossover. The risk of bias was unclear in every one of them.
Outcomes were measured so differently across the studies that very little pooling was possible. What could be pooled:
- Tinnitus loudness on a 0–10 visual analogue scale at one month: mean difference −0.16 (95% CI −1.01 to 0.70), 81 participants — not significant, and rated very low-quality evidence.
- Tinnitus Severity Index at 12 weeks, from one study: mean difference 0.02 (−1.05 to 1.09), 50 participants — moderate-quality evidence, and about as close to zero as a result gets.
Nothing was reported on depression, anxiety, quality of life or tinnitus intrusiveness, because none of the studies measured them.
The authors' conclusion is a specific kind of negative, and the wording matters: there is an absence of evidence that betahistine affects subjective idiopathic tinnitus compared with placebo. That is not the same as evidence of absence, and Cochrane does not claim it is — but with five trials and no signal, the practical implication is the same.
On safety the review is reassuring: betahistine is generally well tolerated, with a risk of adverse effects similar to placebo, and no reports of upper gastrointestinal discomfort — the significant adverse effect it looked for — in any study.
Cochrane reached the same place from a wider angle in 2023, reviewing systemic pharmacological interventions for Ménière's disease as a class — 10 studies, 848 participants, betahistine among them. Its verdict: the evidence is very uncertain, few randomised trials compare these drugs against placebo or no treatment at all, and what exists is of low or very low certainty.
So on both questions — betahistine for tinnitus, and drug treatment for the condition betahistine is licensed for — the highest-grade synthesis available says the trials needed to answer it have not been done well enough.
Why the gap between prescribing patterns and evidence exists
This is an interesting case of clinical practice outpacing rigorous evidence — betahistine has been used for decades, has a good general safety profile, and clinicians' accumulated experience with individual patients doesn't always align cleanly with what controlled trials measure in aggregate. That gap doesn't necessarily mean either side is wrong — it's a real, acknowledged tension in evidence-based medicine, and part of why formal bodies like NICE specifically flag drugs like this for reassessment despite continued widespread use.
Where the guidelines land
The 2024 guideline from the US Department of Veterans Affairs and Department of Defense suggests against betahistine for tinnitus management. It does so in a single weak recommendation against a list of drugs that also names anticonvulsants, antidepressants, antiemetics, antithrombotics, intratympanic corticosteroid injections and NMDA receptor antagonists. The VA/DoD guideline covers the document as a whole.
What this means practically
If betahistine has been suggested to you for tinnitus specifically (rather than diagnosed Ménière's disease), it's reasonable to ask directly what outcome your prescriber expects and how that aligns with the formal evidence review findings described here — not to refuse the medication outright, since individual response can differ from population-level trial averages, but to have an honest, informed conversation about realistic expectations rather than assuming it's a well-proven tinnitus treatment.